These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15843667)

  • 21. Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial.
    Burkhardt U; Zahn R; Höffler U; Siegler KE; Frilling B; Weber M; Gottwik M; Wehr M; Seidel F; Rosocha S; Tebbe U; Senges J
    Z Kardiol; 2004 Sep; 93(9):671-8. PubMed ID: 15365734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings?
    Anderson JL
    N Engl J Med; 2005 Apr; 352(16):1706-9. PubMed ID: 15843674
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
    Demers C
    Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
    N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
    J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serologic markers of persistent Chlamydia pneumonia infection and long-term prognosis after successful coronary stenting.
    Zairis MN; Papadaki OA; Psarogianni PK; Thoma MA; Andrikopoulos GK; Batika PC; Poulopoulou CG; Trifinopoulou KG; Olympios CD; Foussas SG
    Am Heart J; 2003 Dec; 146(6):1082-9. PubMed ID: 14661003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
    Mehta SR; Yusuf S;
    Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlamydia pneumoniae and acute coronary syndrome.
    Frothingham R
    N Engl J Med; 2005 Aug; 353(5):525-8; author reply 525-8. PubMed ID: 16080249
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibiotic treatment of atherosclerosis.
    Muhlestein JB
    Curr Opin Lipidol; 2003 Dec; 14(6):605-14. PubMed ID: 14624138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial.
    Joensen JB; Juul S; Henneberg E; Thomsen G; Ostergaard L; Lindholt JS
    Atherosclerosis; 2008 Feb; 196(2):937-42. PubMed ID: 17418218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial.
    Neumann F; Kastrati A; Miethke T; Pogatsa-Murray G; Mehilli J; Valina C; Jogethaei N; da Costa CP; Wagner H; Schömig A
    Lancet; 2001 Jun; 357(9274):2085-9. PubMed ID: 11445102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Final confirmation of inefficiency of antibiotics in secondary prevention of coronary heart disease. Results of PROVE IT (gatifloxacin trial) and ACES].
    Pokrovskaia EV
    Kardiologiia; 2004; 44(10):82-3. PubMed ID: 15477798
    [No Abstract]   [Full Text] [Related]  

  • 40. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    Ridker PM; Everett BM; Pradhan A; MacFadyen JG; Solomon DH; Zaharris E; Mam V; Hasan A; Rosenberg Y; Iturriaga E; Gupta M; Tsigoulis M; Verma S; Clearfield M; Libby P; Goldhaber SZ; Seagle R; Ofori C; Saklayen M; Butman S; Singh N; Le May M; Bertrand O; Johnston J; Paynter NP; Glynn RJ;
    N Engl J Med; 2019 Feb; 380(8):752-762. PubMed ID: 30415610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.